NEXGEL, Inc. (NXGL)
| Market Cap | 3.43M -81.8% |
| Revenue (ttm) | 12.07M +3.4% |
| Net Income | -6.19M |
| EPS | -0.75 |
| Shares Out | 9.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,120 |
| Open | 0.3410 |
| Previous Close | 0.3499 |
| Day's Range | 0.3338 - 0.3591 |
| 52-Week Range | 0.3001 - 2.8900 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 17, 2026 |
About NXGL
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central line... [Read more]
Financial Performance
In 2025, NEXGEL's revenue was $11.42 million, an increase of 31.46% compared to the previous year's $8.69 million. Losses were -$3.00 million, -8.56% less than in 2024.
Financial StatementsNews
NexGel downgraded to Hold from Buy at Maxim
Maxim downgraded NexGel (NXGL) to Hold from Buy without a price target NexGel’s Q2 sales miss, slower-than-expected BioNX integration and revenue ramp, unresolved supply-chain and contract issues, and...
NexGel downgraded to Hold from Buy at Maxim
Maxim analyst Naz Rahman downgraded NexGel (NXGL) to Hold from Buy.
NEXGEL Proxy statement: Proxy filing
NEXGEL filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
NexGel CEO Adam Levy to depart, Brian Kieser appointed interim CEO
NexGel (NXGL) announced effective August 21, Brian Kieser has been appointed interim CEO of NexGel. Following the company’s April acquisition of certain assets from Celularity, Kieser became actively ...
NexGel announces strategic review
The board has established a special committee for strategic review and value creation to oversee a review of the company’s operations, asset portfolio, liquidity position, and long-term strategic dire...
NexGel registers to sell 15.25M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 15.25M shares of common stock. The company is not selling any…
NEXGEL Registration statement: Registration filing
NEXGEL filed a registration statement on August 20, 2026, providing details about a securities offering with the SEC.
NEXGEL Quarterly report: Q2 2026
NEXGEL has published its Q2 2026 quarterly earnings report on August 17, 2026.
NEXGEL Earnings release: Q2 2026
NEXGEL released its Q2 2026 earnings on August 17, 2026, summarizing the period's financial results.
NEXGEL Reports Second Quarter 2026 Financial Results
LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ult...
NEXGEL Proxy statement: Proxy filing
NEXGEL filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
NEXGEL Slides: Investor presentation
NEXGEL has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
NEXGEL Transcript: Planet MicroCap Las Vegas 2026
A transformative acquisition and partnership have expanded the regenerative medicine portfolio, established a direct sales force, and positioned the platform for rapid growth. Key new products and a unified commercialization strategy are set to drive market expansion.
NEXGEL Proxy statement: Proxy filing
NEXGEL filed a proxy statement on June 9, 2026, providing details for shareholder voting and corporate governance matters.
NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL Proxy statement: Proxy filing
NEXGEL filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
NexGel announces data from institutional review board clinical study
NexGel (NXGL) announced data from the randomized, 30-patient, single-center institutional review board clinical study, funded by Innovative Optics, a supplier of safety products and personal protectiv...
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduce...
NEXGEL Earnings Call Transcript: Q1 2026
Q1 2026 revenue was $2.65M, down slightly year-over-year, with legacy business flat but showing signs of recovery. The BioNX acquisition is expected to triple annual revenue and be immediately accretive, while integration and new product launches are underway.
NEXGEL Quarterly report: Q1 2026
NEXGEL has published its Q1 2026 quarterly earnings report on May 15, 2026.
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE ...
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa.
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Co...
NexGel appoints Ian Blackman as CFO
NexGel (NXGL) announced the appointment of Ian Blackman as CFO. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerativ...
NEXGEL Transcript: M&A announcement
The acquisition of Celularity's Degenerative Wound segment, backed by Sequence LifeScience, is expected to triple revenue, be immediately accretive, and transform the business into a diversified medical technology platform with strong growth prospects.